Treatment of infections that are susceptible to Ceftriaxone: – respiratory tract infections, especially pneumonia, as well as ear, throat, and nose infections; – infections of the abdominal cavity (peritonitis, biliary tract and gastrointestinal tract infections); – kidney and urinary tract infections; – genital infections, including gonorrhea; – sepsis; – infections of bones, joints, soft tissues, skin, and wound infections; – infections in patients with weakened immune defenses; – meningitis; – disseminated Lyme borreliosis (stages II and i).
Lavaxon powder Composition
active substance: ceftriaxone;
1 vial contains ceftriaxone sodium equivalent to 2.0 g of ceftriaxone.
Lavaxon powder Dosage form
Powder for solution for injection.
Basic physical and chemical properties: crystalline powder from white to yellow-orange color.
Lavaxon powder Pharmacotherapeutic group
Antibacterial agents for systemic use. Other beta-lactam antibiotics. Generation III cephalosporins. Ceftriaxone.
ATX code J01D D04.
Ceftriaxone is a third generation parenteral cephalosporin antibiotic with prolonged action.
Lavaxon powder Mechanism of action
The bactericidal activity of ceftriaxone is due to the suppression of cell wall synthesis. Ceftriaxone is active in vitro against a wide range of gram-negative and gram-positive microorganisms. Ceftriaxone is very resistant to most beta-lactamases (both penicillinases and cephalosporinases) of gram-positive and gram-negative bacteria. Ceftriaxone is usually active against these microorganisms in vitro and in clinical infections (see section “Indications”):
Staphylococcus aureus (methicillinchutlivium), coagulase-negative staphylococci, Streptococcus pyogenes (beta-hemolytic, group A), Streptococcus agalactiae (beta-hemolytic, group B), beta-hemolytic streptococci (groups neither A, nor B)
Note. Methicillin-resistant Staphylococcus spp. resistant to cephalosporins, including ceftriaxone. Also Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes are resistant to ceftriaxone.
Acinetobacter lwoffi, Acinetobacter anitratus (mainly A. baumanii) * Aeromonas hydrophila, Alcaligenes faecalis, Alcaligenes odorans, alkagenoid bacteria, Borrelia burgdorferi, Burkholderia cepacia, Capnocytophaga spp., Citrobacter spp. Escherichia coli, Enterobacter aerogenes * Enterobacter cloacae *, Enterobacter spp. (Others) * Haemophilus ducreyi, Haemophilus influenzae, Haemophilus parainfluenzae, Hafnia alvei, Klebsiella oxytoca, Klebsiella pneumoniae **, Moraxella catarrhalis (formerly Branhamella catarrhalis), Moraxella osloensis spp. (Others), Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella multocida, Plesiomonas shigelloides, Proteus mirabilis, Proteus penneri * Proteus vulgaris, Pseudomonas fluorescens * Pseudomonas spp. (Others) * Providentia rettgeri, Providentia spp. (Others), Salmonella typhi, Salmonella spp. (Group enteritidis), Serratia marcescens, Serratia spp. (Others), Shigella spp., Vibrio spp., Yersinia enterocolitica, Yersinia spp. (Other).
Lavaxone is indicated for the treatment of the following infections in adults and children, including term infants (from birth):
acute otitis media;
complicated urinary tract infections (including pyelonephritis);
infections of bones and joints;
complicated infections of the skin and soft tissues;
The drug can be used for:
treatment of acute complications of chronic obstructive pulmonary disease in adults;
for the treatment of disseminated Lyme borreliosis (early (stage II) and late (stage II)) in adults and children, including newborns aged 15 days;
preoperative prevention of infections at the surgical site;
for the management of neutropenic patients who develop fever with suspected bacterial infection;
for the treatment of patients with bacteremia that has arisen in connection with any of the above infections or if there is a suspicion of any of the above infections.
The drug should be prescribed together with other antibacterial drugs if the possible range of bacterial pathogens does not fall within the spectrum of its action (see Section “Peculiarities of use”).
The official recommendations regarding the appropriate use of antibacterial agents should be taken into account.
Hypersensitivity to ceftriaxone or to any other cephalosporin. A history of severe hypersensitivity reactions (eg, anaphylactic reactions) to any other type of beta-lactam antibacterial agents (penicillins, monobactams and carbapenems).
Ceftriaxone is contraindicated:
Premature infants ≤ 41 weeks of age, taking into account the duration of intrauterine development (gestational age + age after birth) *.
Term infants (≤ 28 days of age):